Adoptive cell therapy is an immunotherapy treatment that involves extracting immune cells from a patient or donor and genetically engineering them to recognize and attack cancer cells. T cells are removed from a patient or donor and then manipulated to express a novel T cell receptor or chimeric antigen receptor (CAR) that is specific to a certain tumor antigen. The genetically modified T cells are then infused back into the patient to induce an antitumor immune response. Adoptive cell therapy is emerging as an effective therapeutic approach for treating various cancers like melanoma, hematological cancers and solid tumors. The technique shows promising results without any serious side effects and offers personalized treatment options.

The global Adoptive cell therapy market is estimated to be valued at US$6903.93 Mn in 2024 and is expected to exhibit a CAGR of 4.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Adoptive cell therapy are Broadcom, Celeno Communications, Infineon Technologies, Espressif Systems Shanghai Co Ltd, GCT Semiconductor Inc., I&C Technology, Intel Corporation, MediaTek, Inc., Microchip Technology Inc. These players are focusing on developing new CAR T-cell therapies and acquiring smaller players to expand their product portfolio.

The growing incidence of cancer worldwide and rising investments in immuno-oncology research are fueling Adoptive Cell Therapy Market Size. According to Globocan 2020, there were around 19.3 million new cancer cases and 10 million cancer deaths in 2020 globally. This growing cancer burden is creating a lucrative market opportunity for novel immunotherapies like adoptive cell therapy.

Technological advancements in genome engineering tools like CRISPR/Cas9 are helping researchers genetically modify T-cells more efficiently. Developments in vector production technologies, cell processing facilities and cryopreservation techniques are further optimizing adoptive cell therapy protocols.

Market Trends

Personalized Medicine – Adoptive cell therapy exemplifies the potential of personalized medicine as it uses a patient’s own immune cells to fight cancer. Growing focus on precision medicine for improved outcomes is driving the adoption of ACT.

Novel Applications – Research is focused on assessing the safety and efficacy of CAR T-cell therapy in other therapeutic areas like neurological disorders, autoimmune diseases, and organ transplantation beyond just hematological cancers and solid tumors. This will expand the clinical applications of adoptive cell therapy.

Market Opportunities

Allogeneic Cell Therapies – Off-the-shelf allogeneic CAR T-cell therapies derived from healthy donor cells can address some of the challenges with autologous CAR T-cell products like manufacturing complexities and costs. This represents a major opportunity area.

Combination Therapies – Combining CAR T-cell therapy with immune checkpoint inhibitors, targeted therapies, and other immunotherapies holds promise to achieve enhanced and durable clinical responses in cancer.

Impact of COVID-19 on Adoptive Cell Therapy Market Growth

The global outbreak of COVID-19 significantly impacted the growth of the adoptive cell therapy market. During the peak months of the pandemic, clinical research and trials related to adoptive cell therapy were temporarily halted due to lockdowns and social distancing measures. The focus of healthcare resources shifted toward managing COVID-19 patients, which led to reduced funding availability for other therapeutic areas including cancer and autoimmune diseases. Moreover, supply chain disruptions caused delays in the procurement of raw materials required for cell manufacturing. This hampered the development of novel CAR T-cell therapies in the pipeline.

However, the post-COVID period is expected to witness accelerated growth opportunities for the adoptive cell therapy market. With economies gradually reopening and research activities resuming, delayed clinical studies are being reinitiated. Players in the market are investing in virtual clinical trials and digital health technologies to make up for lost time during lockdowns. The pandemic has also highlighted the need for developing effective immunotherapies against other diseases to improve patient outcomes. Strong revenue growth is anticipated in the forecast period as regulatory approvals of new adoptive cell therapies broaden the available treatment options.

In terms of value, North America dominates the adoptive cell therapy market and is estimated to account for more than 40% share globally. The large market size is attributed to established healthcare infrastructure, presence of major market players, and higher adoption of high-cost cancer immunotherapy drugs compared to other regions. On the other hand, Asia Pacific exhibits the highest growth potential for adoptive cell therapy. The regional market is projected to expand at a CAGR of over 6% during the forecast period on the back of rising healthcare spending, growing cancer prevalence, and increasing collaborations between global drug developers and local biotech firms. Countries such as China and India are emerging as lucrative outsourcing destinations for cell manufacturing due to availability of low-cost skilled labor and resources.

Get more insights on Adoptive Cell Therapy Market